Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicentric study to compare the immunogenicity, safety and reactogenicity of GSK Biologicals' DTPa-IPV vaccine vs co-administration of GSK's DTPa vaccine and Sanofi-Pasteurs' IPV vaccine at different injection sites, to healthy children.

Next Previous
X
Search
Trial Profile

A multicentric study to compare the immunogenicity, safety and reactogenicity of GSK Biologicals' DTPa-IPV vaccine vs co-administration of GSK's DTPa vaccine and Sanofi-Pasteurs' IPV vaccine at different injection sites, to healthy children.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Oct 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Hib-DTaP-poliovirus vaccine (Primary) ; DTaP vaccine; Poliovirus vaccine inactivated
  • Indications Diphtheria; Pertussis; Poliomyelitis; Tetanus
  • Focus Pharmacodynamics; Registrational
  • Sponsors GlaxoSmithKline

    • Most Recent Events

    • 10 Sep 2008 Actual patient number changed from 450 to 452 as reported by ClinicalTrials.gov.
    • 31 Jul 2008 The actual completion date for this trial is now 1 Jan 2007.
    • 31 Jul 2008 Status changed from in progress to completed according to clinicaltrials.gov record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top